Literature DB >> 25645091

Oxalobacter formigenes: Opening the door to probiotic therapy for the treatment of hyperoxaluria.

Ankush Jairath1, Narendra Parekh, Natalia Otano, Shashikant Mishra, Arvind Ganpule, Ravindra Sabnis, Mahesh Desai.   

Abstract

OBJECTIVE: The aim of this study was to determine the early effect of the administration of Oxalobacter formigenes on the metabolic pattern of patients with calcium oxalate stones, comparing it with potassium magnesium citrate (KMgCit).
MATERIALS AND METHODS: Eighty patients were randomized to receive either 30 mEq of KMgCit or 700 million O. formigenes, both twice a day. Serum creatinine, serum urate, serum calcium and phosphorus, serum intact parathyroid hormone (if serum calcium >10.5 mg/dl) and 24 h urine metabolic evaluation for various metabolites (e.g. oxalate, calcium, phosphorus, citrate, magnesium, urate and creatinine) were evaluated at baseline and 1 month after starting the treatment.
RESULTS: In both groups hyperoxaluria was the most common abnormality, followed by hypercalciuria. The incidence of hyperoxaluria decreased at 1 month compared to baseline in both KMgCit (77.5% vs 37.5%, p = 0.0006) and O. formigenes preparation (82.5% vs 15%, p < 0.0001) groups, while other urinary metabolic abnormalities were similar at baseline and 1 month in both groups. Three patients in the KMgCit had mild self-limiting secondary symptoms.
CONCLUSION: Compared with KMgCit, O. formigenes preparation is more effective in decreasing the incidence of hyperoxaluria, opening the door to probiotic therapy as a potential new weapon against hyperoxaluria.

Entities:  

Keywords:  Hyperoxaluria; Oxalobacter formigenes; probiotic therapy; urolithiasis

Mesh:

Substances:

Year:  2015        PMID: 25645091     DOI: 10.3109/21681805.2014.996251

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  6 in total

Review 1.  Mechanisms of the intestinal and urinary microbiome in kidney stone disease.

Authors:  Aaron W Miller; Kristina L Penniston; Kate Fitzpatrick; José Agudelo; Gregory Tasian; Dirk Lange
Journal:  Nat Rev Urol       Date:  2022-09-20       Impact factor: 16.430

2.  Combination of Oxalobacter Formigenes and Veillonella Parvula in Gastrointestinal Microbiota Related to Bile-Acid Metabolism as a Biomarker for Hypertensive Nephropathy.

Authors:  Xin Li; Li Wang; Shaojun Ma; Shaohui Lin; Chunyan Wang; Haiya Wang
Journal:  Int J Hypertens       Date:  2022-05-17       Impact factor: 2.434

Review 3.  Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Authors:  Ammon B Peck; Benjamin K Canales; Cuong Q Nguyen
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

4.  Oxalate-Degrading Bacillus subtilis Mitigates Urolithiasis in a Drosophila melanogaster Model.

Authors:  Kait F Al; Brendan A Daisley; Ryan M Chanyi; Jennifer Bjazevic; Hassan Razvi; Gregor Reid; Jeremy P Burton
Journal:  mSphere       Date:  2020-09-09       Impact factor: 4.389

5.  Revealing microbial species diversity using sequence capture by hybridization.

Authors:  Sophie Marre; Cyrielle Gasc; Camille Forest; Yacine Lebbaoui; Pascale Mosoni; Pierre Peyret
Journal:  Microb Genom       Date:  2021-12

6.  An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria.

Authors:  David Lubkowicz; Nicholas G Horvath; Michael J James; Pasquale Cantarella; Lauren Renaud; Christopher G Bergeron; Ron B Shmueli; Cami Anderson; Jian-Rong Gao; Caroline B Kurtz; Mylene Perreault; Mark R Charbonneau; Vincent M Isabella; David L Hava
Journal:  Mol Syst Biol       Date:  2022-03       Impact factor: 11.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.